샘플 요청 목록

 카트 문의
시장보고서
상품코드
1777649

세계의 자궁근종 치료제 시장

Uterine Fibroid Treatment Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 376 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 자궁근종 치료제 시장은 2030년까지 36억 달러에 도달

2024년에 21억 달러로 추정되는 세계의 자궁근종 치료제 시장은 분석 기간인 2024-2030년에 CAGR 9.0%로 성장하며, 2030년에는 36억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 고나도트로핀 방출 호르몬 작용제는 CAGR 10.4%를 기록하며, 분석 기간 종료시에는 14억 달러에 달할 것으로 예측됩니다. 고나도트로핀 방출 호르몬 길항제 부문의 성장률은 분석 기간 중 CAGR 6.8%로 추정됩니다.

미국 시장은 5억 7,770만 달러로 추정, 중국은 CAGR 14.2%로 성장 예측

미국의 자궁근종 치료제 시장은 2024년에는 5억 7,770만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 분석 기간인 2024-2030년의 CAGR을 14.2%로 2030년까지 7억 8,930만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 4.5%와 8.6%로 예측됩니다. 유럽에서는 독일이 CAGR 약 6.1%로 성장할 것으로 예측됩니다.

세계의 자궁근종 치료제 시장 - 주요 동향과 촉진요인 정리

자궁근종 유병률 증가로 약물 기반 치료 수요 재구성?

자궁근종(평활근종)은 가임기 여성에게 가장 흔한 양성 종양 중 하나이며, 전 세계 유병률은 여성의 20%-40% 정도가 앓고 있는 것으로 추정됩니다. 자궁근종에 대한 인식이 높아지고, 진단이 개선되고, 의료 서비스에 대한 접근성이 향상됨에 따라 월경과다, 골반통, 불임, 빈혈 등 자궁근종과 관련된 증상으로 치료를 받는 여성의 수가 크게 증가하고 있습니다. 많은 환자들이 자궁적출술이나 자궁근종 적출술과 같은 침습적 수술의 대안으로 약물 치료를 찾는 가운데, 약물 치료가 다시 주목받고 있습니다. 이러한 환자들의 선호도 변화로 인해 자궁근종 치료제의 1차 선택 또는 수술 전 관리 옵션으로 자궁근종 치료제에 대한 수요가 크게 확대되고 있습니다. 자궁근종은 30-40대 여성에게 많이 발생하며, 대부분이 아직 가임기이기 때문에 가임력을 유지하고 긴 회복 기간을 피하는 것이 주요 관심사로 떠오르면서 효과적이고 비수술적인 치료법의 필요성이 더욱 커지고 있습니다. 인종적 격차, 특히 아프리카계 여성의 발병률과 중증도가 높다는 점도 충분한 치료를 받지 못하고 고위험군에 속하는 지역사회의 환자 수 증가에 기여하고 있습니다. 이러한 인구통계학적 및 임상적 역학은 자궁근종 약물 치료 분야의 지속적인 성장을 위한 탄탄한 기반이 되고 있습니다.

새로운 약제 클래스별 및 호르몬제는 어떻게 치료 옵션을 발전시키고 있는가?

의약품의 기술 혁신은 자궁근종 치료의 전망을 빠르게 변화시키고 있으며, 새로운 약물과 개선된 약물은 증상 조절을 강화하고 부작용을 줄이며 편의성을 향상시키고 있습니다. 성선자극호르몬 방출 호르몬(GnRH) 유사체는 자궁근종을 축소하고 대량 출혈을 관리하기 위해 오랫동안 사용되어 왔으나, 골감소증, 안면홍조 등 저에스트로겐성 부작용이 동반되어 장기간 사용에는 한계가 있었습니다. 따라서 선택적 프로게스테론 수용체 조절제(SPRM) 및 경구용 GnRH 길항제 등 안전성 프로파일이 개선되고 보다 표적화된 호르몬 조절을 제공하는 새로운 치료법의 길이 열렸습니다. 에스트라디올이나 노르에틴드론과 병용하는 경우가 많은 릴고릭스와 같은 약물은 현재 효과와 환자의 내약성이 균형 잡힌 효과적인 경구용 치료제로 등장하고 있습니다. 이러한 새로운 약물은 장기적인 증상 관리를 가능하게 하며, 수술적 개입의 대체 또는 보조 수단으로 처방되는 경우가 많아지고 있습니다. 이와 함께 서방형 제제, 병용요법 등 약물전달 기전의 발전으로 환자의 순응도가 향상되고 개인별 맞춤 치료 옵션이 확대되고 있습니다. 새로운 호르몬 조절제, 항섬유화제, 면역 조절 요법을 모색하는 임상시험이 진행 중이며, 자궁근종 치료를 위한 의약품 파이프라인은 그 어느 때보다 역동적으로 변화하고 있습니다. 이러한 기술 혁신은 치료 결과를 개선할 뿐만 아니라, 개인화된 비침습적 자궁근종 관리로 시장 전환을 강화하고 있습니다.

환자 선호도의 변화와 의료 모델의 변화가 비수술적 치료의 채택을 촉진하고 있는가?

세계에서 환자 중심의 최소침습적 치료가 강조되면서 자궁근종 관리 방법이 근본적으로 변화하고 있습니다. 자궁을 보존하고 가임력을 유지하며 수술에 따른 장기적인 다운타임을 피할 수 있는 치료법을 찾는 여성들이 늘고 있습니다. 이 때문에 약물 치료는 특히 증상이 경증에서 중등도인 환자나 수술을 기다리는 환자들에게 매력적인 대안이 되고 있습니다. 또한 외래 치료 모델의 진화와 원격의료 플랫폼의 확대로 원격 진단, 추적관찰, 자궁근종 치료제 처방이 용이해져 자원이 부족한 환경에서도 쉽게 치료를 받을 수 있게 되었습니다. 소비자 직결형 건강 플랫폼과 디지털 웰니스 브랜드도 생리 건강과 자궁근종에 대한 인식을 개선하고 더 많은 여성들이 조기 치료를 받을 수 있도록 돕는 역할을 하고 있습니다. 또한 약물 치료와 자궁동맥색전술(UAE), 집속초음파수술(FUS) 등 다른 비침습적 시술과 결합할 수 있게 됨에 따라 환자와 의료진은 치료 계획의 유연성을 확보할 수 있게 되었습니다. 이에 따라 제약사들은 치료 순응도를 높이고 치료 결과를 개선하기 위해 교육, 환자 지원 프로그램, 지역 사회 홍보에 점점 더 많은 노력을 기울이고 있습니다. 이러한 환자 주도의 기세는 약물 치료가 단독 솔루션으로 또는 보다 광범위한 다중 치료 전략의 구성 요소로 작용할 수 있는 보다 다양하고 종합적인 시장 환경을 형성하는 데 기여하고 있습니다.

자궁근종 치료제 시장의 장기적인 성장을 가속하는 요인은 무엇인가?

자궁근종 치료제 시장의 성장은 임상적 요구, 기술 발전, 환자층의 변화, 진화하는 의료 서비스 제공 시스템의 조합으로 인해 발생합니다. 주요 원동력은 특히 30-50세 여성의 자궁근종 유병률이 전 세계에서 증가하고 있으며, 이 계층은 치료를 받고 생식 건강을 유지하는 데 매우 적극적이라는 점입니다. SPRM과 경구용 GnRH 길항제를 포함한 표적 호르몬 치료제의 파이프라인이 확대되고 있는 것은 장기적으로 보다 안전하고 편리한 관리 옵션을 제공한다는 점에서 환자와 의료진 모두에게 큰 관심을 받고 있습니다. 또한 전 세계 의료 시스템은 만성질환의 비수술적 관리로 전환하고 있으며, 이는 약물 기반 자궁근종 치료의 채택에 유리한 환경을 조성하고 있습니다. 또한 여성 건강 캠페인과 여성 건강 옹호 활동 증가로 월경 건강에 대한 교육이 개선되고 편견이 사라지면서 진단이 빨라지고 약리학적인 해결책에 대한 수요가 증가하고 있습니다. 미국, 유럽, 일본 등 주요 시장에서의 보험급여 승인과 규제 당국의 승인도 제품의 접근성과 상업적 실행 가능성을 높여주고 있습니다. 대형 제약사 및 바이오벤처의 투자가 연구개발을 촉진하고, 디지털 헬스 플랫폼이 보다 광범위한 유통과 환자 참여를 가능하게 하고 있습니다. 이러한 요인들이 결합되어 자궁근종 치료제 시장은 기술 혁신, 접근성, 그리고 점점 더 강화되는 세계 환자 집단에 힘입어 지속적으로 성장하고 있습니다.

부문

약제 클래스별(고나도트로핀 방출 호르몬 작용제, 고나도트로핀 방출 호르몬 길항제, 황체 호르몬 방출 자궁내 디바이스·피임약, 비호르몬약, 기타), 유형별(장막하 자궁근종, 장막내 자궁근종, 점막하 자궁근종, Pedunculated Fibroids), 최종사용자별(병원 약국, 소매 약국, 기타)

조사 대상 기업의 예

  • AbbVie Inc.
  • Abbott Healthcare Pvt. Ltd.
  • Amring Pharmaceuticals Inc.
  • AstraZeneca
  • Bayer AG
  • Biocon Biologics
  • Bristol-Myers Squibb Company
  • Ferring Pharmaceuticals
  • Gedeon Richter plc
  • GlaxoSmithKline plc
  • Hologic, Inc.
  • Hoffmann-La Roche Ltd
  • Ipsen Pharma
  • Kissei Pharmaceutical Co., Ltd.
  • Medtronic
  • Merot Medical Systems
  • Minerva Surgical, Inc.
  • Myovant Sciences GmbH
  • Novartis AG
  • ObsEva

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 일반적인 LLM나 업계별 SLM 쿼리에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.08.06

Global Uterine Fibroid Treatment Drugs Market to Reach US$3.6 Billion by 2030

The global market for Uterine Fibroid Treatment Drugs estimated at US$2.1 Billion in the year 2024, is expected to reach US$3.6 Billion by 2030, growing at a CAGR of 9.0% over the analysis period 2024-2030. Gonadotropin-releasing Hormone Agonists, one of the segments analyzed in the report, is expected to record a 10.4% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Gonadotropin-releasing Hormone Antagonists segment is estimated at 6.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$577.7 Million While China is Forecast to Grow at 14.2% CAGR

The Uterine Fibroid Treatment Drugs market in the U.S. is estimated at US$577.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$789.3 Million by the year 2030 trailing a CAGR of 14.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.5% and 8.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.1% CAGR.

Global Uterine Fibroid Treatment Drugs Market - Key Trends & Drivers Summarized

Is the Rising Prevalence of Uterine Fibroids Reshaping the Demand for Drug-Based Therapies?

Uterine fibroids, or leiomyomas, are one of the most common benign tumors in women of reproductive age, with an estimated global prevalence affecting nearly 20% to 40% of women. The rising awareness, improved diagnosis, and increased healthcare access have significantly boosted the number of women seeking treatment for fibroid-related symptoms such as heavy menstrual bleeding, pelvic pain, infertility, and anemia. As many patients look for alternatives to invasive surgical procedures such as hysterectomy and myomectomy, pharmaceutical interventions are gaining renewed traction. This shift in patient preference has significantly expanded the demand for uterine fibroid treatment drugs as first-line or pre-surgical management options. With fibroids more commonly affecting women in their 30s and 40s-many of whom are still in their childbearing years-preserving fertility and avoiding long recovery times has become a central concern, further propelling the need for effective, non-surgical therapies. Ethnic disparities particularly higher incidence and severity among women of African descent are also contributing to a growing patient pool in underserved and high-risk communities. These demographic and clinical dynamics are creating a robust foundation for sustained growth in the drug-based treatment segment for uterine fibroids.

How Are Novel Drug Classes and Hormonal Agents Advancing Therapeutic Options?

Pharmaceutical innovation is rapidly transforming the landscape of uterine fibroid treatment, with new and improved drugs offering enhanced symptom control, fewer side effects, and greater convenience. Gonadotropin-releasing hormone (GnRH) analogs have long been used to reduce fibroid size and manage heavy bleeding, but their association with hypoestrogenic side effects like bone loss and hot flashes has limited long-term use. This has paved the way for newer therapies such as selective progesterone receptor modulators (SPRMs) and oral GnRH antagonists, which offer more targeted hormonal modulation with improved safety profiles. Drugs like relugolix, often used in combination with estradiol and norethindrone, are now emerging as effective oral therapies that balance efficacy with patient tolerability. These novel agents are enabling long-term symptom management and are increasingly being prescribed as alternatives or adjuncts to surgical intervention. In parallel, advancements in drug delivery mechanisms-such as extended-release formulations and combination therapies-are enhancing patient adherence and expanding options for individualized care. With ongoing clinical trials exploring new hormone regulators, anti-fibrotic agents, and even immune-modulating therapies, the pharmaceutical pipeline for uterine fibroid treatment is more dynamic than ever. These innovations are not only improving therapeutic outcomes but are also reinforcing the market’s shift toward personalized, non-invasive fibroid management.

Are Shifting Patient Preferences and Healthcare Models Driving Non-Surgical Treatment Adoption?

The growing global emphasis on patient-centered, minimally invasive care is fundamentally changing how uterine fibroids are managed-putting greater focus on drug-based interventions. Increasingly, women are demanding treatment options that allow them to preserve their uterus, maintain fertility, and avoid extended downtime associated with surgery. This has made pharmacological therapies an attractive choice, particularly for those with mild to moderate symptoms or those awaiting surgery. Moreover, the evolution of outpatient care models and the expansion of telemedicine platforms are facilitating remote diagnosis, follow-up, and prescription of fibroid treatment drugs, making therapies more accessible even in lower-resource settings. Direct-to-consumer health platforms and digital wellness brands are also playing a role in demystifying menstrual health and fibroid awareness, encouraging more women to pursue medical treatment earlier. Furthermore, the ability to combine drug therapy with other non-invasive procedures, such as uterine artery embolization (UAE) or focused ultrasound surgery (FUS), is giving patients and providers more flexibility in treatment planning. In response, pharmaceutical companies are increasingly focusing on education, patient support programs, and community outreach to encourage adherence and improve outcomes. This patient-driven momentum is contributing to a more diversified and inclusive market landscape, where drug therapies serve as both standalone solutions and components of broader multimodal treatment strategies.

What Factors Are Driving Long-Term Growth in the Uterine Fibroid Treatment Drugs Market?

The growth in the uterine fibroid treatment drugs market is driven by a combination of clinical need, technological progress, changing patient demographics, and evolving healthcare delivery systems. A key driver is the increasing global prevalence of fibroids, particularly among women aged 30 to 50, a demographic that is highly active in seeking care and maintaining reproductive health. The expanding pipeline of targeted hormonal therapies, including SPRMs and oral GnRH antagonists, is providing safer, more convenient options for long-term management, thus drawing greater interest from both patients and providers. Healthcare systems around the world are also shifting toward non-surgical management of chronic conditions, creating a favorable environment for the adoption of drug-based fibroid therapies. Additionally, growing awareness campaigns and women's health advocacy efforts are improving education and reducing stigma around menstrual health, leading to earlier diagnosis and greater demand for pharmacologic solutions. Reimbursement approvals and regulatory endorsements in key markets like the U.S., Europe, and Japan are also bolstering product accessibility and commercial viability. Investment from major pharmaceutical companies and biotech startups alike is fueling research and development, while digital health platforms are enabling broader distribution and patient engagement. Together, these factors are ensuring that the uterine fibroid treatment drugs market continues to grow, driven by innovation, accessibility, and an increasingly empowered global patient population.

SCOPE OF STUDY:

The report analyzes the Uterine Fibroid Treatment Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications, Others); Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids); End-User (Hospital Pharmacies, Retail Pharmacies, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • AbbVie Inc.
  • Abbott Healthcare Pvt. Ltd.
  • Amring Pharmaceuticals Inc.
  • AstraZeneca
  • Bayer AG
  • Biocon Biologics
  • Bristol-Myers Squibb Company
  • Ferring Pharmaceuticals
  • Gedeon Richter plc
  • GlaxoSmithKline plc
  • Hologic, Inc.
  • Hoffmann-La Roche Ltd
  • Ipsen Pharma
  • Kissei Pharmaceutical Co., Ltd.
  • Medtronic
  • Merot Medical Systems
  • Minerva Surgical, Inc.
  • Myovant Sciences GmbH
  • Novartis AG
  • ObsEva

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Uterine Fibroid Treatment Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Prevalence of Uterine Fibroids Spurs Sustained Demand for Drug-Based Treatment Alternatives
    • Increased Preference for Fertility-Preserving and Non-Surgical Therapies Strengthens Business Case for Pharmacologic Options
    • Advancements in Hormonal Drug Classes and Targeted Therapies Propel Innovation in Symptom Management
    • Growing Patient Awareness and Early Diagnosis Trends Expand the Addressable Market for Medical Treatment
    • Shift Toward Personalized Medicine and Symptom-Specific Formulations Drives Adoption Among Reproductive-Age Women
    • Postponement of Childbearing and Changing Reproductive Health Trends Fuel Demand for Uterus-Conserving Therapies
    • Regulatory Approvals and Market Entry of Oral GnRH Antagonists Create New Competitive Opportunities
    • Expansion of Telehealth and Direct-to-Consumer Gynecology Services Accelerates Access to Treatment Options
    • Rising Investments in Women's Health Research and Drug Development Strengthen the Therapeutic Pipeline
    • Increased Emphasis on Quality of Life and Menstrual Health Throws Spotlight on Long-Term Medical Management Solutions
    • Combination Therapy Approaches Generate Opportunities for Multifaceted and Extended Treatment Plans
    • Digital Education Campaigns and Advocacy Efforts Drive Patient Engagement and Reduce Stigma Around Fibroid Management
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Uterine Fibroid Treatment Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Uterine Fibroid Treatment Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Uterine Fibroid Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Gonadotropin-releasing Hormone Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Gonadotropin-releasing Hormone Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Gonadotropin-releasing Hormone Agonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Gonadotropin-releasing Hormone Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Gonadotropin-releasing Hormone Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Gonadotropin-releasing Hormone Antagonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Progestin-releasing Intrauterine Device & Contraceptives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Progestin-releasing Intrauterine Device & Contraceptives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Progestin-releasing Intrauterine Device & Contraceptives by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Non-hormonal Medications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Non-hormonal Medications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Non-hormonal Medications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Subserosal Fibroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Subserosal Fibroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Subserosal Fibroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Intramural Fibroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Intramural Fibroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Intramural Fibroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Submucosal Fibroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Submucosal Fibroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Submucosal Fibroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Pedunculated Fibroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Pedunculated Fibroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Pedunculated Fibroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • JAPAN
    • Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • CHINA
    • Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • EUROPE
    • Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Uterine Fibroid Treatment Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Uterine Fibroid Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • FRANCE
    • Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: France 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • GERMANY
    • Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Germany 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Italy 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: UK 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Spain 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Spain 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Russia 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Russia 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Uterine Fibroid Treatment Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Australia 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Australia 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • INDIA
    • Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 173: India Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: India 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: India 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: South Korea 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: South Korea 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Uterine Fibroid Treatment Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Uterine Fibroid Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Latin America 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Argentina 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Argentina 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Brazil 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Brazil 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Mexico 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Mexico 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Uterine Fibroid Treatment Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Uterine Fibroid Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Middle East 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Iran 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Iran 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Israel 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Israel 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: UAE 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: UAE 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • AFRICA
    • Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Africa 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Africa 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제